FindTrial
Sign In

Fluoropyrimidine (capecitabine or 5-fluorouracil)

DRUG2 trials

Sponsors

The Netherlands Cancer Institute

Conditions

Neoplasms

Unknown Phase

Safety, Feasibility and Cost-effectiveness of Genotype-directed Individualized Dosing of Fluoropyrimidines
CompletedNCT02324452
The Netherlands Cancer InstituteNeoplasms
Start: 2015-03-31End: 2018-03-31Updated: 2018-05-11
Improving the Safety of Fluoropyrimidine-based Chemotherapy
NCT04194957
The Netherlands Cancer InstituteNeoplasms
Start: 2020-01-15End: 2021-01-31Target: 1440Updated: 2020-01-22

Related Papers

Discovering novel germline genetic variants linked to severe fluoropyrimidine-related toxicity in- and outside DPYD.
2024-08-155 citations
A Nomogram to Predict Severe Toxicity in DPYD Wild‐Type Patients Treated With Capecitabine‐Based Anticancer Regimens
Clinical Pharmacology & Therapeutics2023-11-148 citations
Survival of Patients With Cancer With <i>DPYD</i> Variant Alleles and Dose-Individualized Fluoropyrimidine Therapy-A Matched-Pair Analysis.
2023-08-2835 citations
A cost analysis of upfront DPYD genotype-guided dose individualisation in fluoropyrimidine-based anticancer therapy.
2018-12-1162 citations
DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis.
2018-10-19288 citations